Selective RXR Agonist Compounds for Lower-Side-Effect Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions such as Alzheimer's disease, Parkinson's disease, diabetes, cancer, and psychotic disorders like schizophrenia suffer from nonspecific RXR binding, leading to severe side effects due to the use of compounds like bexarotene, which interact with various RXR forms, including homodimers and heterodimers.
Innovation Solution
Development of novel compounds, specifically those of Formula (I), which act as selective RXR agonists, targeting specific RXR pathways to modulate transcription and reduce side effects by binding selectively to RXR.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bexarotene is used to treat conditions such as Alzheimer's disease, Parkinson's disease, diabetes, cancer, and psychotic disorders, then therapeutic benefits are achieved through RXR activation, but severe side effects occur due to nonspecific binding to various RXR forms including homodimers and heterodimers
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formula I and Formula II) that selectively bind to particular RXR heterodimer configurations. The compounds contain specific structural features including aromatic rings, heteroatoms, and substituent patterns that confer selectivity for RXR-TR or RXR-RAR heterodimers while avoiding binding to RXR homodimers or other non-target complexes, thereby achieving therapeutic effects with reduced side effects
Solution Approach 2:
The patent employs parameter changes by systematically modifying molecular parameters such as substituent types (R1-R6 groups), ring structures, and molecular weight to optimize selectivity. By varying these chemical parameters, the compounds achieve differential binding affinities for different RXR forms, enabling selective activation of desired biological pathways while minimizing off-target effects
2Productivity
If RXR agonists are used to activate or repress biological pathways for therapeutic results, then treatment effectiveness is improved, but nonspecific binding to multiple RXR states leads to adverse reactions
Solution Approach 1:
The patent uses intermediary principles by designing compounds that act as selective mediators between the therapeutic goal and the RXR system. These compounds preferentially bind to specific RXR heterodimer intermediates (such as RXR-TR or RXR-RAR) that are responsible for desired therapeutic effects, while avoiding intermediates that lead to adverse reactions, thereby guiding the biological response toward therapeutic outcomes
3Object-affected harmful factors
If compounds are designed to bind selectively to specific RXR pathways, then side effects are reduced, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the compound structure into distinct functional modules (Formula I and Formula II components) with specific roles. Each segment (aromatic ring, heteroatom-containing group, substituent patterns) contributes to specific binding interactions, allowing the molecule to achieve selectivity through modular design rather than through overall molecular complexity
Data Source
AI summary
The invention provides compounds formula (I) and salts thereof: wherein R1-R2 have any of the values defined in the specification. The compounds are useful for treating conditions including Alzheimer's disease, Parkinson's disease, diabetes, cancer, inflammation, hyperresponsiveness, allergic conditions, asthma, and psychotic disorders such as schizophrenia. The compounds are also useful to lower IL-4, IL-5, or IL-15 levels in an animal.